Pavan Vaddady, Merck & Co., Inc.

Pavan Vaddady currently serves as an Executive Director, Quantitative Pharmacology & Pharmacometrics – Oncology at Merck & Co., Inc., where he leads a team of quantitative clinical pharmacologists advancing Merck’s oncology portfolio. During his career, he led several early and late-stage development programs across multiple therapeutic areas both as a clinical pharmacologist and a pharmacometrician and applied model informed approaches to impact key drug discovery and development decisions. Prior to his current role, he was the Head of Advanced Pharmacometrics, Quantitative Clinical Pharmacology at Daiichi Sankyo, Inc., where he led a global team of scientists working on advanced modeling projects involving multiple oncology assets. Pavan is passionate about teaching and mentoring colleagues and currently holds the position of Adjunct Professor at the University of Tennessee Health Science Center. He is also an elected Member of the Board of Trustees at the International Society of Pharmacometrics (ISoP).